DarioHealth Corp. (NASDAQ:DRIO) Given Average Rating of “Hold” by Brokerages

DarioHealth Corp. (NASDAQ:DRIO) has been assigned an average recommendation of “Hold” from the five analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $40.00.

A number of analysts recently issued reports on DRIO shares. Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a research note on Wednesday, October 8th. Wall Street Zen raised shares of DarioHealth to a “sell” rating in a research report on Saturday, October 11th. Finally, Cowen restated a “hold” rating on shares of DarioHealth in a report on Friday.

DarioHealth Stock Performance

DarioHealth stock opened at $10.53 on Friday. The company has a quick ratio of 2.83, a current ratio of 3.30 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $23.95 million, a price-to-earnings ratio of -0.80 and a beta of 1.19. DarioHealth has a 12-month low of $5.93 and a 12-month high of $31.00. The stock has a 50-day simple moving average of $12.56 and a 200 day simple moving average of $12.74.

DarioHealth (NASDAQ:DRIO) last issued its earnings results on Thursday, November 13th. The company reported ($2.96) EPS for the quarter, missing the consensus estimate of ($2.63) by ($0.33). DarioHealth had a negative net margin of 162.73% and a negative return on equity of 65.89%. The business had revenue of $5.01 million for the quarter, compared to the consensus estimate of $5.67 million. On average, research analysts anticipate that DarioHealth will post -1.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DarioHealth stock. AMH Equity Ltd acquired a new stake in DarioHealth Corp. (NASDAQ:DRIO) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 250,000 shares of the company’s stock, valued at approximately $153,000. AMH Equity Ltd owned about 0.60% of DarioHealth at the end of the most recent reporting period. 33.39% of the stock is owned by institutional investors.

DarioHealth Company Profile

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.